Weekly paclitaxel in patients with CAP-resistant advanced or recurrent endometrial carcinoma: a series of four patients

Abstract

We evaluated the feasibility of weekly paclitaxel in patients with recurrent or advanced endometrial carcinoma who had failed treatment with cyclophosphamide, doxorubicin, and cisplatin (CAP). We treated four patients with CAP-resistant recurrent or advanced endometrial carcinoma with paclitaxel. Paclitaxel (80 mg/m(2); infused over 1 h) was administered weekly for a maximum of 18 weeks, unless disease progression or intractable toxicity developed. A complete response was observed in one patient and a partial response in two patients. Disease progression was found in one patient. Two patients developed grade 3 leukopenia or neutropenia. Neurotoxicity for all patients was within grade 1. Outpatient treatment with weekly paclitaxel was well-tolerated and feasible for patients with CAP-resistant recurrent or advanced endometrial carcinoma. Further trials to confirm the efficacy and toxicity of weekly paclitaxel are warranted.

A phase II trial of weekly 1-hour paclitaxel as second-line therapy for endometrial and cervical cancer

“…[25][26][27] Two more recent preliminary studies of weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer have shown response rates of 67% and 75%, but in small numbers (6/9 and 3/4, respectively) of patients. 24,28 Because response in fi rst-line therapy is often double that in second-line therapy, the present series response rate of 26.7% compares favorably with these recent reports.…”

“…[14][15][16][17] In addition, more recent studies have reported that similar regimens (60-100 mg/m 2 per week) continue to be well tolerated and have an improved therapeutic index even in patients with advanced ovarian, endometrial, and breast cancers. 18,19,[21][22][23][24] Several fi rst-line phase II studies of paclitaxel in disseminated endometrial cancer reported overall response rates of up to 30%. [25][26][27] Two more recent preliminary studies of weekly 1-h paclitaxel infusion in patients with recurrent endometrial cancer have shown response rates of 67% and 75%, but in small numbers (6/9 and 3/4, respectively) of patients.…”

A systematic review of platinum and taxane resistance from bench to clinic: An inverse relationship

“…Hence our study populations were more likely to be homogenous. Other platinum-resistant carcinomas which have been treated with paclitaxel based salvage therapy include testicular [144][145][146][147] , NSCLC 148,149 , urothelial 150 , bladder 151 and endometrial carcinomas 152 .…”